R&D In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Titan's Spheramine fails in Parkinson's: Titan Pharmaceutical's Parkinson's disease drug Spheramine missed its primary endpoints and key secondary endpoints in a Phase IIb STEPS study, the firm announced July 2. Spheramine, which is injected into the brain to enhance dopamine, was tested in patients not getting sufficient control with oral medication. No difference was seen between the treatment arm and the sham surgery arm after 12 months of follow-up. Titan's partner, Bayer Schering, is halting development of the cell-based therapy
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class